Delivering the impossible for our clients.

BDD Logo WHITE.png

BDD combines drug delivery expertise and clinical capabilities to accelerate product development pipelines, enable life cycle management and create new value-added products. Rapid parallel clinical testing with BDD SWIFT significantly reduces the time from product concept to clinical success. 

Prove your product claims with BDD Scintigraphy, best in class scintigraphic clinical trials. 

A unique patented time release technology, OralogiK™ provides unrivalled control of drug release at the right place and the right time to achieve a superior and clinically effective drug delivery profile.

BDD SWIFT for rapid clinical development. SWIFT accelerates evaluation and optimisation of product performance using in vivo clinical data to direct formulation design in real time.  SWIFT studies enable you to make decisions on formulation changes based on emerging clinical data.  This integration of formulation development, GMP manufacturing and clinical testing activities can reduce the time from initial prototype development to clinical results to just 6 months.

Our Vision

BDD aims to be the number one integrated pharmaceutical development centre. Because we recognise that one size does not fit all we specialise in providing responsive, flexible and innovative solutions to our customers.


Our success is built upon solid scientific ability, strengthened by shared values across the company. Our commitment to our clients is at the forefront of everything we do; we always keep our promise and deliver when we say we will. We are a company of integrity and value and we take pride in everything that we do.

The Board

LinkedIn Photos-11 (4).jpg

Joanne Kelley


Joanne Kelley has a long and extensive experience of global commercial and general management in the pharmaceutical industry and has led a range of transactions including M&A, technology licensing and collaboration arrangements. Previously in her role as Vice President of Business Development, Head of Transactions at AstraZeneca, Jo was responsible for a number of transformational deals and has received a number of awards recognising her deal making achievements. As well as her position as Chair of BDD, Jo is a non- executive Director for The University of Manchester Innovation Factory, a Director of Alderley Park Ventures and a Business Development consultant for UK lifescience companies.

Carol Thomson 



Dr Carol Thomson has had a varied career in management in the science sector and developed strong operational management and leadership skills at Thomson Reuters, where she managed the Pharmaceutical Patents Business Unit of the World Patents Index. Following this, Carol spent three years at the University of Strathclyde in a Research Business Development role and subsequently as Research Policy Manager. Carol has a degree in Genetics and PhD from the University of Sheffield.


Howard Stevens

  Executive Director

Professor Howard Stevens is a registered pharmacist whose career spans four decades of management of industrial research and development in the UK and Europe in large multinationals and small drug delivery companies. He has been involved in the formation of several successful spin-out businesses and served as the Pfizer Professor of Drug Delivery at the University of Strathclyde from 1998-2009. He has an extensive scientific and patent publication record, is a fellow of the RPSGB, RSC and APSGB and served as Chairman of the APSGB in 2001.

Stephen Brown

Non-Executive Director

Stephen is a PhD Pharmacist (Queens University, Belfast) with 30+ years experience in Pharmaceutical product development. During his career he has worked with a number of large Pharma and Biotech companies including Sterling Winthrop, Sanofi, Chiroscience, Celltech, and UCB. He has experience with a wide range of dosage forms, (oral and injectable), drug delivery technologies and devices and established and led Pharmaceutical Development teams responsible for the successful development of a number of new chemical entities (NCEs) and antibody products with total peak annual sales in excess of $3Bn, including Oxaliplatin and Cimzia. 

Glenn Crocker MBE

 Non-Executive Director


Dr Glenn Crocker has a first degree in Genetics and a DPhil in Immunology from Oxford University. He qualified as a chartered accountant with Ernst & Young and worked in the life science practice for a number of years where he focused on advising the biotechnology industry, spending several years in Palo Alto, California, and returning to Cambridge to head the UK biotechnology practice for the firm, focusing on business development and corporate finance transactions.